18922 (2026). Hon Dr Ayesha Verrall to the Associate Minister of Health

Written Question

Published date: 24 May 2026

Metadata

Document type:	Written Question
Parliament number:	54
Question number:	18922 (2026)
Question asked:	10 May 2026
Member asking:	Hon Dr Ayesha Verrall
Portfolio:	Associate Minister of Health
Minister replying:	Hon David Seymour
Answer received:	19 May 2026
Status:	Question Answered
Reply type:	Reply
Document ID:	WQ_18922_2026
Document guid:	734e6f7a-7c1e-4b73-89c5-9b3cb212b247

18922 (2026). Hon Dr Ayesha Verrall to the Associate Minister of Health: Has blinatumomab been funded by Pharmac for the treatment of precursor B-cell acute lymphoblastic leukaemia in patients in complete haematological remission with measurable residual disease; and if not, is it under consideration for funding?

Hon David Seymour: I am advised by Pharmac that an application for blinatumomab for this indication has been received and is currently under assessment. I refer the Member to the following link for more information: https://connect.pharmac.govt.nz/apptracker/s/application-public/a10OZ000000e52b/p002022